Form 4: Quest Diagnostics SVP & General Counsel Michael E. Prevoznik Reports Stock Sale

Michael E. Prevoznik, SVP & General Counsel of Quest Diagnostics, reports the sale of 4,643 shares of common stock at $170 per share on March 17, 2025, and indirectly owns 5,641 shares through a 401(k)/SDCP.

Summary

• On March 17, 2025, Michael E. Prevoznik, the SVP & General Counsel of Quest Diagnostics, sold 4,643 shares of common stock.
• The sale was executed at a price of $170 per share.
• The transaction was conducted under a pre-arranged Rule 10b5-1 sales plan.
• Following the reported transaction, Prevoznik directly owns 38,117 shares of Quest Diagnostics.
• Prevoznik also indirectly owns 5,641 shares through the company's 401(k) and Supplemental Deferred Compensation Plan (SDCP).

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting a stock sale by an executive. It doesn't inherently convey positive or negative sentiment.

Industry Context

This is a routine disclosure of insider trading activity. It is common for executives to have pre-arranged trading plans (Rule 10b5-1) to avoid accusations of trading on inside information.

Stakeholder Impact

• The stock sale could have a minor negative impact on shareholder sentiment, but is unlikely to be significant given the relatively small number of shares sold and the pre-planned nature of the transaction.

Key Dates

Keywords

Quest Diagnostics, Michael E. Prevoznik, Stock Sale, Form 4, DGX, Rule 10b5-1, Insider Trading, Securities Exchange Act, Beneficial Ownership, 401(k), SDCP